EPHA3 (Ifabotuzumab Biosimilar) Recombinant Monoclonal Antibody

1. High EPHA3 expression is associated with tumor growth and angiogenesis in gastric cancer. PMID: 30066881
2. To investigate the relationship between five EPHA3 single nucleotide polymorphisms (SNPs) and Nonsyndromic Cleft Lip With or Without Cleft Palate (NSCL/P), EPHA3 SNPs (rs7650466, rs1398197, rs17801309, rs1054750, and rs7632427) were genotyped. The rs7650466 T allele was associated with the incidence of NSCL/P as well as with protective and dominant effects in both conditions. PMID: 29932736
3. Although EPHA3 was reported to be one of the most frequently mutated genes in colorectal tumors, our studies using inducible isogenic cell line systems, mouse models and large human tumor collections, did not reveal a major role of this EPH receptor on proliferation/motility/invasion of cancer cells, tumor initiation/progression/metastasis in mouse models or survival of colorectal cancer patients. PMID: 28169277
4. The interaction of AR and SP1 contributes to regulate EPHA3 expression. PMID: 29917167
5. Findings suggest that EPH receptor A3 (EphA3) plays an important role in the pathogenesis of multiple myeloma (MM). PMID: 28721629
6. Study shows that EphA3 is highly overexpressed in multiple myeloma (MM) and provides evidence that EphA3 plays an important role in MM angiogenesis. PMID: 28415715
7. Results indicate that EphA3 protein expression is reduced in clear-cell renal cell carcinoma, suggesting the possibility that this receptor functions as a tumor suppressor in this disease. PMID: 27591824
8. EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic signaling pathways. PMID: 27721017
9. Data indicate that EPHA3 is involved in regulating the multidrug resistance (MDR) of small cell lung cancer (SCLC) via PI3K/BMX/STAT3 signaling and may be a therapeutic target in SCLC. PMID: 27101199
10. PTP-PEST regulates EphA3 activation both by affecting cytoskeletal remodelling and through its direct action as a PTP controlling EphA3 phosphorylation. PMID: 26644181
11. This study showed that EPHA3 gene involved in neuronal growth and cerebellum development and associated with neurological and psychological disorders. PMID: 26381449
12. A novel association between the EPHA3 deletion and prostate cancer risk was observed in Finnish individuals. PMID: 26552734
13. EphA3 forms dimers in the absence of ligand binding. PMID: 26232493
14. Data indicate that hypoxia increased EphA3 receptor (EphA3) mRNA expression in EphA3+ endometrial multipotent mesenchymal stromal cells (eMSCs). PMID: 25420155
15. EphA3 was induced by PC-1 and contributed to the malignant progression of prostate cancer PMID: 25231727
16. Based on the knowledge that EPHA4 has been previously shown to rescue SOD1 transgenic mice from ALS phenotype and prolongs survival, EPHA3 may be a promising candidate for therepuetic interventions PMID: 23991104
17. EphA3 may represent a novel candidate marker for patient prognosis as well a molecular target for HCC therapy. PMID: 23970317
18. EPHA3 mutations may promote tumorigenesis only when key senescence-inducing pathways have been inactivated. PMID: 23324396
19. EphA3 may play important roles in the angiogenesis and prognosis of gastric carcinoma PMID: 22350700
20. High EphA3 expression is associated with glioblastoma multiforme. PMID: 23410976
21. Cancer-associated EPHA3 mutations attenuate the tumor-suppressive effects of normal EPHA3 in lung cancer. PMID: 22829656
22. EphA3 has ephrin- and kinase-dependent tumor suppressing activities, which are disrupted by somatic cancer mutations PMID: 22242939
23. expression of EphA3 and CD133 in carcinoma was significantly higher than that in normal mucosal tissue PMID: 21415057
24. Experiments in EphA3/Isl2 knock-in mice test the interactions between effects of molecular labels and correlated activity during the development of neural connectivity. PMID: 21190559
25. Authors found significant association between the copy number variations of EphA3 and hematologic malignancies. PMID: 21454190
26. Data shew that the identification of three novel candidates as EPH receptor genes might indicate a link between perturbed compartmentalization of early neoplastic lesions and breast cancer risk and progression. PMID: 21124932
27. Data provide further support that ALS2CL, EPHA3, and CMYA1 are bona-fide tumor-suppressor genes and contribute to the tumorigenesis of HNSCC. PMID: 20657180
28. EphA3, was identified as a new CD28-responsive gene in Jurkat cells by using a human cytokine/receptor array. EphA3 expression in CD28-stimulated Jurkat cells was enhanced by IGF-1 or by overexpression of the IGF-1R. PMID: 14697337
29. Results show EPHA3 gene was implicated in the pathogenesis of lung cancer and it may be useful targets for diagnostic and therapeutic intervention in selected patients. PMID: 16941478
30. High-resolution structures of the EphA3 kinase with and without the juxtamembrane segment allowed mapping of the coupled pathway of residues that connect the juxtamembrane segment, the activation loop, and the catalytic residues of the kinase domain. PMID: 18547520
31. EphA3 expression may define subsets of rhabdomyosarcoma tumours, and that EphA3 suppresses motility through regulation of Rho GTPases in rhabdomyosarcoma cells. PMID: 18814179
32. D219V missense mutation in EPHA3 is associated with hepatocellular carcinoma. PMID: 19469653
33. mechanism of substrate binding PMID: 19678838

Show More

Hide All

HGNC: 3387

OMIM: 114500

KEGG: hsa:2042

STRING: 9606.ENSP00000337451

UniGene: Hs.123642